标题
Selinexor for advanced hematologic malignancies
作者
关键词
-
出版物
LEUKEMIA & LYMPHOMA
Volume -, Issue -, Pages 1-16
出版商
Informa UK Limited
发表日期
2020-06-15
DOI
10.1080/10428194.2020.1775210
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
- (2020) Maria Gavriatopoulou et al. LEUKEMIA
- A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
- (2020) David E. Gordon et al. NATURE
- Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
- (2019) Andrzej J. Jakubowiak et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer
- (2019) Michael Shafique et al. ONCOLOGIST
- Inhibitors of nuclear transport
- (2019) David A Jans et al. CURRENT OPINION IN CELL BIOLOGY
- NUCLEAR EXPORT INHIBITION ENHANCES THE ACTIVITY OF R-CHOP IN NON-HODGKIN'S LYMPHOMA
- (2019) A.S. Azmi et al. HEMATOLOGICAL ONCOLOGY
- A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
- (2019) N. Kalakonda et al. HEMATOLOGICAL ONCOLOGY
- Altered nuclear export signal recognition as a driver of oncogenesis
- (2019) Justin Taylor et al. Cancer Discovery
- Final analysis from RESONATE: up to 6 years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
- (2019) Talha Munir et al. AMERICAN JOURNAL OF HEMATOLOGY
- Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study
- (2019) Bhavana Bhatnagar et al. LEUKEMIA & LYMPHOMA
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study
- (2019) Deborah M. Stephens et al. BLOOD
- Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome
- (2019) Sangmin Lee et al. BLOOD
- Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
- (2019) Kendra Sweet et al. CLINICAL CANCER RESEARCH
- Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia
- (2019) Ramzi Abboud et al. HAEMATOLOGICA
- Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma
- (2019) Tim J. Peterson et al. ANNALS OF PHARMACOTHERAPY
- Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma
- (2019) Asfar S. Azmi et al. CLINICAL CANCER RESEARCH
- Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- (2019) Meghan Salcedo et al. Clinical Lymphoma Myeloma & Leukemia
- Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies
- (2019) I.B. Vergote et al. GYNECOLOGIC ONCOLOGY
- Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies
- (2019) Isha Kapoor et al. Cell Death & Disease
- FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models
- (2018) Cristina Corno et al. BIOCHEMICAL PHARMACOLOGY
- Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
- (2018) Weiguo Zhang et al. HAEMATOLOGICA
- Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
- (2018) Dan T. Vogl et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
- (2018) Amy Y. Wang et al. Journal of Hematology & Oncology
- Correlation of CRM1-NES affinity with nuclear export activity
- (2018) Szu-Chin Fu et al. MOLECULAR BIOLOGY OF THE CELL
- A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer
- (2018) Xiao X. Wei et al. ONCOLOGIST
- Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death
- (2018) Christian Argueta et al. Oncotarget
- Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
- (2018) Weiguo Zhang et al. HAEMATOLOGICA
- Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1
- (2018) Daniel A. Luedtke et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.
- (2018) Mrinal M. Gounder et al. JOURNAL OF CLINICAL ONCOLOGY
- In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals
- (2018) Douglas G. Widman et al. PLoS One
- Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
- (2018) Nizar J. Bahlis et al. BLOOD
- Verdinexor (KPT-335), a selective inhibitor of nuclear export, reduces RSV replication in vitro
- (2018) Patricia A. Jorquera et al. JOURNAL OF VIROLOGY
- Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement
- (2017) Sabela Bobillo et al. HAEMATOLOGICA
- Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen
- (2017) Michael Schaffer et al. LEUKEMIA & LYMPHOMA
- Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
- (2017) Barbara Muz et al. Translational Oncology
- In vitro evaluation of Selective Inhibitors of Nuclear Export (SINE) drugs KPT-185 and KPT-335 against canine mammary carcinoma and transitional cell carcinoma tumor initiating cells
- (2017) J. E. Grayton et al. Veterinary and Comparative Oncology
- Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer
- (2017) Giovanni Luca Gravina et al. Oncotarget
- Selective Inhibitors of Nuclear Export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3
- (2017) Young Hwa Soung et al. Oncotarget
- Inhibition of exportin-1 function results in rapid cell cycle-associated DNA damage in cancer cells
- (2017) Russell T. Burke et al. Oncotarget
- CRM1 Inhibitors for Antiviral Therapy
- (2017) Cynthia Mathew et al. Frontiers in Microbiology
- Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement
- (2017) Sabela Bobillo et al. HAEMATOLOGICA
- Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
- (2017) Manoj Garg et al. Scientific Reports
- Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma
- (2016) Fabrice Jardin et al. AMERICAN JOURNAL OF HEMATOLOGY
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone
- (2016) Irfana Muqbil et al. CANCER LETTERS
- CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling
- (2016) H. Sun et al. CANCER RESEARCH
- Anti-inflammatory natural product goniothalamin reduces colitis-associated and sporadic colorectal tumorigenesis
- (2016) Débora Barbosa Vendramini-Costa et al. CARCINOGENESIS
- Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
- (2016) Ying Chen et al. CLINICAL CANCER RESEARCH
- XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase II to the Nucleus
- (2016) P. Ranganathan et al. CLINICAL CANCER RESEARCH
- The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
- (2016) Sarah E.M. Herman et al. CLINICAL CANCER RESEARCH
- XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells
- (2016) Cheryl Taylor-Kashton et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia
- (2016) Thomas B. Alexander et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
- (2016) Albiruni R. Abdul Razak et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma
- (2016) Mrinal M. Gounder et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
- (2016) Joel G. Turner et al. Journal of Hematology & Oncology
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
- (2016) J Etchin et al. LEUKEMIA
- Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies
- (2016) Z A Hing et al. LEUKEMIA
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection
- (2016) Olivia Perwitasari et al. PLoS One
- Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma
- (2016) Manoj Garg et al. Oncotarget
- Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
- (2016) Robert Nakayama et al. Oncotarget
- Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia
- (2015) Z. A. Hing et al. BLOOD
- Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia
- (2015) P. Ranganathan et al. BLOOD
- shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance
- (2015) J. S. Khorashad et al. BLOOD
- A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
- (2015) S. M. O'Brien et al. BLOOD
- Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds
- (2015) Marsha Crochiere et al. BMC CANCER
- KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
- (2015) Giovanni Luca Gravina et al. BMC CANCER
- Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing
- (2015) Jasper E. Neggers et al. CHEMISTRY & BIOLOGY
- XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer
- (2015) I. Ferreiro-Neira et al. CLINICAL CANCER RESEARCH
- The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
- (2015) K Balakrishnan et al. LEUKEMIA
- Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice
- (2015) J Etchin et al. LEUKEMIA
- CRM1 as a new therapeutic target for non-Hodgkin lymphoma
- (2015) Xiaohong Han et al. LEUKEMIA RESEARCH
- Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor
- (2015) S. Rosebeck et al. MOLECULAR CANCER THERAPEUTICS
- Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin
- (2015) Michelandrea De Cesare et al. Oncotarget
- A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds
- (2015) Marsha L. Crochiere et al. Oncotarget
- Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition
- (2015) Asfar S. Azmi et al. Scientific Reports
- A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning
- (2015) Koray Kırlı et al. eLife
- Structural determinants of nuclear export signal orientation in binding to exportin CRM1
- (2015) Ho Yee Joyce Fung et al. eLife
- LocNES: a computational tool for locating classical NESs in CRM1 cargo proteins
- (2014) Darui Xu et al. BIOINFORMATICS
- Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines
- (2014) Megan N Breit et al. BMC Veterinary Research
- KPT-330 has antitumour activity against non-small cell lung cancer
- (2014) H Sun et al. BRITISH JOURNAL OF CANCER
- KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma
- (2014) Yun Zheng et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)
- (2014) Giovanni Gravina et al. Journal of Hematology & Oncology
- Verdinexor, a Novel Selective Inhibitor of Nuclear Export, Reduces Influenza A Virus Replication In Vitro and In Vivo
- (2014) O. Perwitasari et al. JOURNAL OF VIROLOGY
- Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells
- (2014) Y Zhong et al. LEUKEMIA
- CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
- (2014) N. Saito et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma
- (2014) Adam L. Green et al. NEURO-ONCOLOGY
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study
- (2014) Cheryl A. London et al. PLoS One
- Specific Inhibition of the Nuclear Exporter Exportin-1 Attenuates Kidney Cancer Growth
- (2014) Hiromi I. Wettersten et al. PLoS One
- Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents
- (2014) Joel G. Turner et al. SEMINARS IN CANCER BIOLOGY
- Prognostic impact and targeting of CRM1 in acute myeloid leukemia
- (2013) K. Kojima et al. BLOOD
- Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias
- (2013) C. J. Walker et al. BLOOD
- KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia
- (2013) Julia Etchin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas
- (2013) A. S. Azmi et al. HAEMATOLOGICA
- Release of Severe Acute Respiratory Syndrome Coronavirus Nuclear Import Block Enhances Host Transcription in Human Lung Cells
- (2013) A. C. Sims et al. JOURNAL OF VIROLOGY
- Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276
- (2013) J Schmidt et al. LEUKEMIA
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
- (2013) Y-T Tai et al. LEUKEMIA
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia
- (2012) R. Lapalombella et al. BLOOD
- Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia
- (2012) P. Ranganathan et al. BLOOD
- Two palmitylated cysteine residues of the severe acute respiratory syndrome coronavirus spike (S) protein are critical for S incorporation into virus-like particles, but not for M-S co-localization
- (2012) M. Ujike et al. JOURNAL OF GENERAL VIROLOGY
- Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells
- (2012) J Etchin et al. LEUKEMIA
- Sequence and structural analyses of nuclear export signals in the NESdb database
- (2012) Darui Xu et al. MOLECULAR BIOLOGY OF THE CELL
- Nuclear export of proteins and drug resistance in cancer
- (2011) Joel G. Turner et al. BIOCHEMICAL PHARMACOLOGY
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML)
- (2011) Sarah M. Larson et al. LEUKEMIA & LYMPHOMA
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
- (2011) Xose S. Puente et al. NATURE
- SARS-CoV 9b Protein Diffuses into Nucleus, Undergoes Active Crm1 Mediated Nucleocytoplasmic Export and Triggers Apoptosis When Retained in the Nucleus
- (2011) Kulbhushan Sharma et al. PLoS One
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo
- (2009) S. C. Mutka et al. CANCER RESEARCH
- The Respiratory Syncytial Virus Matrix Protein Possesses a Crm1-Mediated Nuclear Export Mechanism
- (2009) R. Ghildyal et al. JOURNAL OF VIROLOGY
- Molecular Determinants for Subcellular Localization of the Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame 3b Protein
- (2009) E. C. Freundt et al. JOURNAL OF VIROLOGY
- Structural basis for assembly and disassembly of the CRM1 nuclear export complex
- (2009) Xiuhua Dong et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: Structure–activity relationship and mechanism of action
- (2008) Tine Van Neck et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Combined Analysis of Murine and Human Microarrays and ChIP Analysis Reveals Genes Associated with the Ability of MYC To Maintain Tumorigenesis
- (2008) Chi-Hwa Wu et al. PLoS Genetics
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now